LOOK AT THIS STOCK, TAKE IT APART THEN DISSECT IT AGAIN A PUT IT THROUGH THE MIXER---IT WILL COME UP TRUMPS---EVERY TIME!

Look at the profitabilty of the new company, the products the market and the quality of the board.

At these prices this share is cheap.

PLEASE PROVE ME WRONG!

this is a solid good quality company..profit taking going on now but it'll be back up and more in the next few yrs....(imo)

Let the foolish ones ride alone skyhigh, its obvious that they are opportunists who cant see a proper deal if it hit them in the eye.

You have been doing that for years...it is clear you are fool by your heading...you can't even get that right..

A mis presented heading always gets attention, you really are quite limited in preception--why is that?

Would be much better for you to observe and avoid continually making a fool of yourself.

MLR is one of many companies in its field...a very small company in a very large world.

Very high risk.

Of course it is.

Arnt they all?

But dont we love the risk/reward?

If you want to score over the next two years, please study this company well.

Research the hell out of it and then you will see that buying into it is a sound investment.

Its a brand new company now and its only just starting to grow.

I cant say more than that.

Chatting around today chaps only to find a consensus between holders that there is no other reason for MLR to be marked down other than MMs sentiments.

Dont be fooled this is s great buying opportunity. as the company is A OK.

The SP will continue to decline until there is some positive news and this company has once again reported a loss...so IMHO the SP will decline rapidly.

BMW FORMALLY SQUELCHED SO YOU ARE TALKING TO YOURSELF AS USUAL.

Boo Hoo

Now, now , now baby BMW please dont be childish, some one will give your dummy back I am sure, meanwhile please dip deep into MLR you will make a mint in a very short time. FACT

I mean we are here to make money not trade insults.

Trading of insults you can do in any back street pub, but making money, real money takes education and class not crass.

You have just advised cynic to "come back in 2 years"...now you say I will make a mint in a short time.

The FACT is you do not appear to know the difference between FACT or FICTION.

come, come, come Sir in the magical world of stocks and shares two years is a very conservative short term, by the way, what world are you from?

furthermore you would be doing me a favour if you kept criticising MLR even though you have obviously not researched it-----and further by not, yes not buying it.

IN FACT BMW PLEASE DONT BUY IT!

Research...they are still making a loss, thats all the research I need to know.

Have a nice day.

Please Sir your ignorance is showing:-


Given the old saying that where ignorance is bliss etc I draw attention to the recent results below, I would also imagine that MLR have a lot of tax credits from all those unprofitable years - should help with the EPS.

I would estimate as a minimum that the Acorus acquisition should add at least 1m profitability to MLR. It would also seem that Maelor's organic growth should seem them produce at least a further 0.5m profitability in the next 12 months.

That gives an estinated PER of 11.5 based on current market cap of around 17.5m.

They will now prove to be a rapid growing company with I would have thought a PER of 15-20 being appropriate.

That possibly equates to potential share price growth over the next 12 months of 50-100% with a bit more if MLR are able to exceed expectations. Seems like good value to me with limited downside on a 12 month view, but please dont buy it stick to COH.

A BIT MORE FOR YOU---- CHEW ON IT WHILE CONSIDERING YOUR IGNORANCE!

Acorus audited results for year ended 30 September 2006

Acorus reported turnover of #3.04 million for the year ended 30 September 2006 (year ended 30 September 2005: #1.59 million).



Maelor PLC
05 June 2007


5th June 2007

Maelor plc

('Maelor', 'Group' or 'Company')


Maelor results ahead of expectations - profitable in H2


Preliminary Results for the year ended 31st March 2007


Maelor plc (AIM: MLR), the specialist hospital medicines company, announces
preliminary results for the year ended 31st March 2007.


Financial Highlights - Results ahead of expectations - profitable in H2

- Turnover up 53% to 2.84m (2006: 1.86m)
- Operating loss down to 73k (2006:609k / H1 93k)
- Earnings/loss per share reduced to 0.10p (2006:1.93p)
- Net cash position improved to 1.43m (2006:1.10m)

Operational Highlights - Transformational year

- Strong performance from underlying business

- Volplex sales tripled Vs 2005/06
- ISOplex and AquiHex into late stage development and on schedule
- Licence secured to supply 'specials'
- Initial payment received for Micelle Lidocaine
- 8% improvement in gross margin to 48% (2006: 40%)

- Further strengthened management team

- New Finance Director & Commercial Manager

- Transforming acquisition of Acorus Therapeutics Limited ('Acorus')
post year end

- Enlarged group profitable and growing
- Highly synergistic portfolio of products
- Integration progressing to schedule


Tim Wright, Chief Executive of Maelor plc said:


'This year has been transformational for Maelor. In line with our new strategy
developed in 2005/6 we have focused the Company on late stage and launched
products, managed the business to profitability in the second half of the year
and completed the acquisition of Acorus, thereby creating a substantial
specialist hospital medicine business which is profitable and cash generative.


Trading since the period end is in line with expectations and the integration of
Acorus is, as anticipated, proceeding smoothly. The enlarged business provides
us with a platform for further growth both organically and through further
acquisitions.'

- Ends -

For further information, call:
Tim Wright, Chief Executive T: +44(0) 1244 625150
Maelor plc

Matthew Hall/Sam Reynolds T: +44(0)20 7763 2200
Noble & Company Limited

Billy Clegg/Edward Westropp T: +44(0)20 7831 3113
Financial Dynamics


Chairman's Statement


Introduction


I am pleased to present the results for the past financial year, a year of
significant achievements for Maelor. Under the leadership of our CEO, Tim Wright
, the new management team has worked to transform the Company into a profitable
business with a focus on late stage specialist hospital medicines.


In my statement in the 2005-06 Annual Report I noted that for Maelor to
accelerate its growth we needed to succeed in marketing core products in our own
right and in partnering non-core products. In the year end March 2007 we
achieved both of these objectives with a threefold increase in sales of Volplex
and the exploitation of our micelle technology in a partnership with Plethora.
In addition we have further expanded our portfolio of critical care products
with the addition of AquiHexTM and ISOplexTM.


Our financial performance this year is much improved with the company reaching
breakeven in the second half of the year, resulting from an outstanding 53%
revenue growth. Our cash position has also strengthened and margins have been
substantially improved.



Acquisition


Since the year end, we have delivered a transforming, earnings enhancing
acquisition, which has made us profitable and built a strong platform for
growth. Acorus is a successful specialist pharmaceuticals and medical devices
company, which we acquired for a total consideration of 13 million. The initial
cash consideration was satisfied by the issue to institutional investors of
80,000,000 new Ordinary Shares of 10 pence each, which raised 8 million and was
oversubscribed.


Acorus is significantly profitable and growing with a portfolio of assets
primarily focused in critical care and neurology. It was established in 2000 and
has been built as a virtual company; thus the speed and success of our
integration process to date.


Outlook


Trading since the period end is in line with expectations and the integration of
Acorus is on schedule.


The existing business is now performing well. The acquisition of Acorus, with
its portfolio of marketed products will make us significantly profitable
creating a strong platform upon which to grow the business both organically and
through further acquisitions. The Board would like to thank the Maelor team for
its efforts and achievements during the year and it looks to the future with
confidence.


Chief Executive's Review


In my report last year we outlined our strategy to transform Maelor into a
specialist hospital medicine business, focused initially in critical care. We
identified the importance of focusing on late stage products, thereby reducing
the risk and expense of early stage development as well as leveraging our
non-critical care portfolio through efficient partnerships.


I am pleased to report that the implementation of this plan is progressing well
and has been significantly accelerated following the recently announced;
transforming acquisition of Acorus, creating a strong and profitable enlarged
Company.


Separating out the recent acquisition of Acorus, I am also pleased to report
that the underlying Maelor business has performed well over the year and in
particular has delivered a strong and profitable second half:

Building a specialist hospital medicines business


A significant contributor to this performance has been the successful
re-acquisition and re-launch of Volplex, a product Maelor originally developed
and licensed. Used in operating theatres and wards to maintain blood volume,
Volplex competes primarily with one other long established product.


We have succeeded in trebling sales of Volplex since March 2006 and MAT (moving
annual total) market share has grown from 12% to 20%. We have recruited an
experienced Commercial Manager and with substantial room for further market
share growth, the management team is confident that Maelor can continue to win
new customers and further grow sales of Volplex.


During the year we announced the late stage development of ISOplex and AquiHex,
both products which will be used in critical care settings. ISOplex, in common
with Volplex will be used in situations where an increase in blood volume is
required. ISOplex has been designed to mimic natural blood plasma, particularly
in the balance of electrolytes. The use of these 'isotonic' formulations is an
area of significant interest amongst critical care clinicians. Given our
experience and existing data in this sector it is anticipated that development
will be relatively rapid and inexpensive for a pharmaceutical product.
Development has continued to progress on schedule and regulatory approval
remains to be forecast for the end of 2008.


AquiHex is a 2% aqueous formulation of chlorhexidine, an antibacterial product
commonly used prior to surgical incision or insertion of IV lines. To date all
products of this type are alcohol based and therefore present problems in
settings where flammability is of concern such as operating theatres. Use of
alcohol based products is also recommended against when using certain IV lines
as it can make them brittle. AquiHex is being supplied as a 'special' ahead of
registration, which is currently forecast for late 2009.


In the middle of the year we succeeded in gaining approval to supply un-licensed
medicines. Generally known as 'specials' these products can be requested by
physicians for use in patients where there is a specific requirement which is
presently unmet by any medicine licensed in the UK. In addition to establishing
closer relationships with the critical care community this strategy will enable
Maelor to gauge demand for products and where this demand is sufficient,
progress these products to licence in the UK. We have recently gained
distribution rights to a selection of fluid and volume replacement products from
Germany which we also make available as part of this service.


Leverage non-critical care portfolio through efficient partnerships


We will continue to select strong partners to commercialise the heritage
portfolio of products and technologies that do not fit directly with the
Company's hospital specialist strategy, in particular our catheter flushing
solutions OptiFlo and Contisol and our proprietary early stage micelle
nanotechnology.


OptiFlo, the UK brand of catheter flushing solutions distributed by Bard,
continues to perform well, with sales up 6% versus 2005/2006, and remains the UK
market leader with a market share of 54%.


Included in the first half of the year is an initial payment following the
licensing of our proprietary micelle nanotechnology, micelle lidocaine. The
partnership with Plethora Solutions Holdings plc, a specialist urology company,
is progressing well and the product has successfully passed through the first
stage of its preclinical development programme. Under the terms of the
agreement Plethora is responsible for product development and distribution and
Maelor is entitled to milestone and royalty payments. The micelle lidocaine
technology will be incorporated into Plethora's on going product development
programme for the treatment of interstitial cystitis and painful bladder
syndrome. These distressing conditions are estimated to afflict up to two
million women in the United States and Europe.



Financial Summary


Financial results for the year ended 31 March 2007 have been delivered ahead of
expectations.


Turnover for the year to 31 March 2007 was 2.84m (2006: 1.86m), representing
an increase of 53% over prior year. This significant increase can be attributed
to the management team's continued focus on growing Volplex, the sales growth of
Optiflo as well as an initial payment received for our micelle lidocaine
nanotechnology.


Gross margins increased from last year by almost 8% to 48% as a result of
further efficiencies in manufacturing and supply.


The Group's operating loss for the year reduced significantly to 73k from 609k
in 2006, including achieving a 20k operating profit in the second half of the
year. The improvement was driven by the sales growth, the initial licensing
payment and careful cost control.


Group cash balances, net of debt, at 31 March 2007 were 1.43m compared with
1.10m last year. At the end of the year we sold our office building and
relocated to a modern leasehold property on Chester Business Park. Proceeds from
the sale of the building enabled the bank mortgage to be cleared leaving the
Company debt free at the year end. Since the year end we have negotiated a 2.0m
bank facility for further business expansion.



Acquisition of Acorus Therapeutics Limited


In line with the Company's strategy the most recent achievement was to
successfully complete a deal to acquire privately owned Acorus for a total
consideration of approximately 13.0m, comprising 7.0m in cash, 10 million
ordinary shares at 10p each and loan notes of 4.88m, contingent on achievement
of certain sales milestones.


The deal was funded by an oversubscribed placing of 80 million 10p ordinary
shares issued at 10p each and was completed on 10 May 2007. It is a transforming
move for Maelor, with the enlarged group becoming immediately profitable and
cash generative.


Acorus is a particularly synergistic acquisition. The product range is
complementary to Maelor's with the same customers, distribution channels and
regulatory systems and processes. The integration process is progressing well
and on schedule.


Outlook


Our vision remains to build a new force in specialist hospital medicine,
leveraging our expertise in both pharmaceuticals and medical devices. We have
re-focused the business, taken it to profitability in the second half and in
Acorus made a synergistic transformational acquisition. With a strong team in
place, Maelor is well-positioned to drive growth organically and through
acquisition.

This revenue generated gross profit of #2.13 million in 2006 (2005: #1.10 million) and made a profit after tax of #0.62 million (2005: profit of #0.04 million).

JUST A SMALL DETAIL OF AN "OPERATING LOSS", KEEPS ME FROM JUMPING IN...JUST A POSSIBILITY IT COULD GET WORSE....LOLOLOLOL

HAVE A NICE DAY.

Obviously you cant read, so stay ignorant and dont buy it!

Your loss.

Don't worry I won't...nobody in their right mind would buy either.